IMF_logo_RGB.png
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
January 12, 2024 08:45 ET | International Myeloma Foundation
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at ASH 2023
Picture1.png
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023 20:30 ET | Autolus Therapeutics plc
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Agios_2021_Logo.png
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
December 09, 2023 19:00 ET | Agios Pharmaceuticals, Inc.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Aptose Biosciences Inc. logo
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023 18:30 ET | Aptose Biosciences, Inc.
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
Cellectis Logo.png
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
November 02, 2023 16:30 ET | Cellectis Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Novalgen_logo_on_white.jpg
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
November 02, 2023 15:18 ET | NovalGen Ltd.
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting
TIP_link_300x300.jpg
Fly Ash Market to Reach $45.73Bn by 2028 at 4.8% CAGR with Type C Fly Ash Segment Driving Growth During 2021–2028 | The Insight Partners
July 05, 2023 07:55 ET | The Insight Partners
Pune, India, July 05, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Fly Ash Market Size Report, Share, Growth Strategy, Industry Trends, and Forecast to 2028-...
Florida Cancer Specialists & Research Institute Well Represented at 64th American Society of Hematology (ASH) 64th Annual Meeting
Florida Cancer Specialists & Research Institute Research Breakthroughs Presented at Global Hematology Gathering
December 13, 2022 09:17 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the...
Spark Therapeutics Logo
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
December 12, 2022 12:00 ET | Spark Therapeutics, Inc.
Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and infusion ratesData shared during...
Logo.jpg
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
December 12, 2022 07:30 ET | GT Biopharma, Inc.
Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE...